Background: Cancer remains a major public health hazard despite the extensive research over the years on cancer diagnostic and treatment , this is mainly due to the complex pathophysiology and genetic makeup of cancer. A new approach toward cancer treatment is the use of cancer vaccine, yet the different molecular bases of cancers reduce the effectiveness of this approach. In this work we aim to use matrix metalloproteinase-9 protein (MMP9) which is essential molecule in the survival and metastasis of all type of cancer as a target for universal cancer vaccine design. Method: reference sequence of matrix metalloproteinase-9 protein was obtained from NCBI databases along with the related sequence, which is then checked for conservation using BioEdit, furthermore the B cell and T cell related peptide were analyzed using IEDB website. The best candidate peptide were then visualized using chimera software. Result: Three Peptides found to be good candidate for interactions with B cells (SLPE, RLYT, and PALPR), while ten peptides found as a good target for interactions with MHC1 (YRYGYTRVA, YGYTRVAEM, YLYRYGYTR, WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR , MYPMYRFTE, FLIADKWPA) with world combined coverage of 94.77% . In addition, ten peptides were also found as a good candidates for interactions with MHC2 (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS), with world combined coverage of 90.67%. CONCLUSION: 23 peptide-based vaccine was designed for use as a universal cancer vaccine which has a high world population coverage for MHC1(94.77%) and MHC2 (90.67%) related alleles.
Prediction of surface accessibility:
By using Emini surface accessibility prediction tool of the immune epitope database (IEDB) (http://tools.immuneepitope.org/tools/bcell/iedb ).
[29] The surface accessible epitopes were predicted from the conserved region holding the default threshold value 1.000. we selected all peptides with values less than this threshold for further analysis.
Prediction of epitopes antigenicity :
The kolaskar and tongaonker antigenicity method was used to determine the antigenic sites with a default threshold value of
It is available at (http://tools.immuneepitope.org/bcell/ ),[30] all antigenic peptide with values less than the threshold were selected for further analysis.
T cell epitope prediction:

MHC class I binding predictions:
Peptide binding to MHC class I molecules was analyzed by the IEDB MHC I prediction tool (http://tools.iedb.org/mhc1.) ; based on Artificial Neural Network (ANN) .this tool has different algorithms to show the ability of the submitted sequence to bind to a specific MHC class 1 molecule. (38, (41) (42) (43) All epitope lengths were set as 9 amino acids, all conserved epitopes that bind to alleles at score equal or less than 100 half-maximal inhibitory concentration (IC50) is selected for further analysis.(44)
MHC class II binding predictions:
Peptide binding to MHC class II molecules was analyzed by the IEDB MHC II prediction tool (http://tools.iedb.org/mhcII ) (45, 46) the three major types of HLA alleles (DR, DQ and DP) were chosen for analysis based on NN-align, and all peptide with IC50 less than 500 were chosen for further workout.
Population coverage:
Diverse HLA alleles are very distributable world-wide population. Hence, the HLA-alleles distribution among the world population is critical for effective multi-epitope vaccine design. Predicted population coverage analysis of above-mentioned MHC class I and II epitopes were done by using IEDB tool against world-wide population. (http://tools.iedb.org/tools/population/iedb_input).(47)
3D Modeling:
The full 3D structure of MM9 was generated by RaptorX (http://raptorx.uchicago.edu/).(48) The accession number of the reference sequence is NP-004985.2 then UCSF Chimera was used to visualize the position of suggested peptides.(49) the modeling was then verified using Ramachandran plot from the model panel in chimera software.
Allergenicity test:
AllerTOP v. 2.0 was used to check the allergenicity of MMP9 protein. The method is based on auto cross covariance (ACC) transformation of protein sequences into uniform equal-length vectors. It depends on five E descriptors of amino acids ( amino acid hydrophobicity, molecular size, helix-forming propensity, relative abundance of amino acids, and β -strand forming propensity). The proteins are classified depending on training sets containing different known and unknown allergens.(50) It is available at https://www.ddgpharmfac.net/AllerTOP/index.html.
Antigenicity test:
VaxiJen v. 2.0 was used to check the antigenicity of the chosen peptides with a cut point of 0.5. It is an alignment-free approach to in silico antigen identification, based on the auto cross covariance (ACC) method. It has a prediction accuracy ranging from 69% to 97 %.(51) The software is available at http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html.
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P r e d i c t i o n o f interferon-gamma inducing epitopes:
IFNepitope was used to predict the MHC2 related peptides with a capacity to activate interferon gamma cytokine productions. It is based on two models: Motif based and SVM based models. (52) The software is available at http://crdd.osdd.net/raghava/ifnepitope/index.php.
Results:
Prediction of B cell epitope:
The metalloproteinase-9 protein (MMP-9) reference sequence was examined by using Bepipred linear epitope prediction, Kolaskar and Tongaonkar antigenicity and Emini surface accessibility methods in IEDB, to confine the probability of specific regions in the protein to bind to B cell receptor, being in the surface and immunogenic, respectively.
In bepipred linear epitope prediction method which was the first method used to determine the B cell epitopes, the average binder's score of MMP-9 protein to B cell was 0.321, with a minimum score of -0.006 and a maximum score of 3.227, Basically all values that equal or greater than the default threshold 0.350 were potentially linear epitopes. as shown in (table 1 and figure 1) . In Emini surface accessibility prediction, for an efficient B-cell epitope the average surface accessibility areas of the protein was scored as 1.000, with a maximum of 6.034 and a minimum of 0.031, so all the values equal or greater than the default threshold 1.000 were potentially in the surface. As well as, Kolaskar and Tongaonkar antigenicity prediction's the average of antigenicity was 1.028, with a maximum of 1.307 and minimum of 0.869; all values equal to or greater than the default threshold 1.028 were potential antigenic determinants. The results of conserved predicted B cell epitopes that passed both Emini & kolaskar tests are shown in (table 2 and figure 2&3 ). 
Prediction of T cell epitope:
MHC-I binding profile prediction for T cytotoxic cell conserved epitopes:
227 epitopes were anticipated to interact with di erent MHC-1 alleles. The core epitopes (YRYGYTRVA/ YGYTRVAEM) were noticed to be the dominant binders with 7 alleles for each (HLA-C*06:02,HLA-C*07:01,HLA-C*12:03,HLA-C*14:02,HLA-B*27:05,HLA-C*07:02,HLA-B*39:01/HLA-C*03:03,HLA-C*14:02,HLA-C*12:03,HLA-C*06:02,HLA-B*08:01,HLA-C*15:02,HLA-C*07:01). Followed by (YLYRYGYTR, WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR, MYPMYRFTE, FLIADKWPA) which binds with (8, 5, 5, 3, 3, 5, 1, 3) alleles. (Table 3) . Table 3 : List of most promising epitopes that had a good binding affinity with MHC-I alleles in terms of IC50. 5  5  5  5  6  3  3   K  L  F  G  F  C  P  T  R  3  2  4  3  3  2  5   M  Y  P  M  Y  R  F  T  E  4  1  9  4  2  7  1   F  L  I  A  D  K  W  P  A  5  5  4  5  6  2  3   MHC-II binding profile prediction for T helper cell conserved epitopes: 479 conserved predicted epitopes were found to interact with MHC-II alleles. The core epitopes (KMLLFSGRRLWRFDV) is thought to be the top binder as it interacts with 18 alleles; (HLA-DRB1*01:01,HLA-DRB1*03:01,HLA-DRB1*04:02,HLA-DRB1*07:01,HLA-DRB1*04:04,HLA-DRB1*08:01,HLA-DRB1*09:01,HLA-DRB1*13:01,HLA-DRB1*11:01,HLA-DRB1*13:02,HLA-DRB1*12:01,HLA-DRB1*15:01,HLA-DRB1*16:02,HLA-DRB3*01:01,HLA-DRB4*01:03,HLA-DRB5*01:01,HLA-DRB3*03:01,HLA-DRB4*01:01). Followed by (GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS) which binds to (17, 17, 18, 14, 14, 17, 15, 14, 14) alleles. (Table 4 ). 
Population coverage analysis
Population coverage test was performed to detect the world Coverage of all epitopes binds to MHC1 alleles and MHC11 alleles, Exhibit an exceptional coverage with percentages of 94.77%, 90.67%. Respectively, as well as selected most promising epitopes for each test. Population coverage for MHC1: ten epitopes are given to interact with the most frequent MHC class I alleles (YRYGYTRVA, YGYTRVAEM, YLYRYGYTR, WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR, MYPMYRFTE a n d FLIADKWPA), representing a considerable coverage against the whole world population. The maximum population coverage percentage over these epitopes worldwide was found to be 62.74% for YRYGYTRVA (table 5, figure 4). Population coverage for MHC11: In the case of MHC class II, ten epitopes were assumed to interact with the most frequent MHC class II alleles (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS), inferring a massive global coverage. The highest population coverage percentage of these epitopes worldwide was that of
with percentage of 83.74% % (table 6, figure 5). 
Illustrates the global proportion for the top ten MHC-II epitopes (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, NQLYLFKDGKYWRFS). Notes: In the graph, the line (-o-) represents the cumulative percentage of population coverage of the epitopes; the bars represent the population coverage for each epitope.
Antigenicity analysis:
Antigenicity analysis of the 10 chosen peptides of MHC1 and MHC2 by vaxiJen software shows four peptides to be probable antigenic peptides in MHC1 (YLYRYGYTR, WRFDVKAQM, LIADKWPAL, and MYPMYRFTE) while only one peptides was found to be antigenic in MHC2 (RRLWRFDVKAQMVDP). (Table 7 ). 
Prediction of interferon-gamma inducing epitopes:
IFNepitope server showed three peptides in MHC2 with an ability to induce interferon-gamma production. (GPFLIADKWPALPRK, GRGKMLLFSGRRLWR, and FARAFALWSAVTPLT). Table 8 . 
Structure modeling and validation by chimera:
MMP9 protein structure was modeled by chimera software and the chosen peptides related to B cell, MHC1 and MHC2 peptides were then visualized.( figure 6,7, and 8). Furthermore, the modeling was verified using the Ramachandran plot in chimera software, which shows that most of the amino acids residues are located i the allowed region. (Figure 10 ). 
Discussion:
Multi Epitope peptides will be the next generation of cancer immunotherapy. However, an efficient vaccine progression and production are costly and time consuming, but the development of immunoinformatics tools has made a broader way in developing vaccines through understanding the immune response within a short amount of time.(53) Many research aimed to design universal cancer vaccines using different approaches, yet until now, there is no FDA approved universal cancer vaccine. (54) The current work used immunogenic protein (matrix metalloproteinase-9) that is essential for the survival of all type of cancer as a target for vaccine design, where three Peptides found to be good candidate for interactions with B cells, in addition ten peptides found as a good target for interactions both MHC1 and MHC2. The different soft wares used for the analysis are summarized in Figure ( 56) In the current work, Linear B cell epitopes of matrix metalloproteinase-9 analyzed by Bepipred linear epitope prediction tool. After checking for conservation using BioEdit software (figure 11), the epitopes were checked for surface accessibility and antigenicity by using the Emini surface accessibility prediction method and Kolaskar and Tongaonkar antigenicity method respectively. (Figure 1,2, and 3) The following peptides have the highest score and were approved as the most promising B cell epitopes (SLPE, RLYT, and PALPR). (Table 1 and 2).
T cell receptor can only identify epitopes if it is presented on major histocompatibility complex, Epitopes binds in linear form to MHCs, they linked together into the binding groove of MHC class I and class II through interactions with the amino acids located in the pockets on the floor of MHC.(57, 58)
Cytotoxic T cell(CD8) can only recognize antigen when it is presented on MHC1, and so we analyzed the peptides that has the highest population coverage to and the best binding MHC1 and found 10 candidates(YRYGYTRVA, YGYTRVAEM,YLYRYGYTR,WRFDVKAQM, ALWSAVTPL, LLLQKQLSL, LIADKWPAL, KLFGFCPTR , MYPMYRFTE, FLIADKWPA) (Table 3 )( Figure 4 ). It is interesting to note that among the associated alleles related to these peptides, we found the most frequent reported allele in Caucasians which is HLA-A*0201.(59) This further proves the significant coverage of these peptides.
In the case of T helper cells, it can only recognize antigen when it is presented in MHC2. Therefore, we predicted the peptides of MMP9 that can firmly bind with MHC2, which also hold the highest population coverage and end up with the following 10 peptides sequence (KMLLFSGRRLWRFDV, GRGKMLLFSGRRLWR, RGKMLLFSGRRLWRF, GKMLLFSGRRLWRFD, TFTRVYSRDADIVIQ, AVIDDAFARAFALWS, FARAFALWSAVTPLT, MLLFSGRRLWRFDVK, GNQLYLFKDGKYWRF, and NQLYLFKDGKYWRFS). (Table 4 )( Figure 5 )
The population coverage of the epitopes and their respective HLA alleles are crucial, as HLA alleles are highly polymorphic in nature. (60) We aim for this vaccine to benefit patient from different parts of the world, therefore, we analyzed the whole word population coverage for our predicted peptide, where we found MHC1 and MHC2 to have population coverage of 94.77% and 90.67% Respectively (Table 5 and 6). Therefor our vaccine is assumed to elicit a strong comprehensive immune response against our targeted protein matrix Metallopeptidase 9 (MMP9) in the majority of vaccinated population.
All peptides were visualized using chimera software (Figures 6 ,7 , and 8) which shows the predicted structures and positions of these peptides in MMP9 protein( yellow color), then Ramachandran plot analysis shows most of the amino acids residue located in the allowed regions which validate the accuracy of the generated structure. (61) Allergencity is an important factor in vaccine design as allergic reaction could be fatal to the patients and hence we tested the allergencity of our proposed vaccine using allertop software which confirm the non allergencity of the vaccine.(62) Furthermore the antigenicity is a significant factor to tack into account when choosing a target for vaccine design ,(63) therefore we tested the antigenicity of mhc1 and mhc2 peptide using vaxiJen software which shows 4 peptides to be antigenic in mhc1(YLYRYGYTR, WRFDVKAQM, LIADKWPAL, MYPMYRFTE) and one peptide to be antigenic in mhc2 (RRLWRFDVKAQMVD). (Table 7) Interferon gamma is a cytokine that plays an essential role in the innate and adaptive immunity. It is produced from T cell upon activation by specific peptides which lead to improvement in cancer elimination by inducing ischemia and improving recognition of the tumor cells by CD4 and CD8 cells.(64) we tested the ability of our chosen peptide to induce secretion of interferon gamma through IFNepitope software which indicate that there is 3 peptides in MHC 2 to positively affect the interferon gamma production (GPFLIADKWPALPRK, GRGKMLLFSGRRLWR, FARAFALWSAVTPLT ) (Table 8 ).
In a study done by Roomi et al, where they used MMP9 as anticancer vaccine in mice, they found 80% reduction in tumor volume after using this vaccine.(65)Which further proves the predicted effectiveness of our proposed vaccine. We took further step in our work to analyze this target using human database, which confirm our hypothesis about the role of MMP9 as a good candidate for vaccine.
Previous research by Dosset et al. designed a universal peptide based cancer vaccine using telomerase reverse transcriptase (TERT) which showed improve response against CD4 and CD8, but the role of B cell was not investigated in this research. (66) This study is limited due to the few numbers of reference sequence we were able to acquire from NCBI, along with the 6 alleles(HL-DRB3*03:01, HL-DRB3*02:01, HL-DRB4*01:03, HL-DRB3*01:01, HL-DRB4*01:01, HL-DRB5*01:01) that was not applicable for prediction in IEDB.in addition to the limited therapeutic activity of peptide vaccine in general. (67) In the end, 23 peptides were chosen as a target for universal cancer vaccine design, yet Wet lab studies are required to confirm these results, in order to move another step towered the goal of eradicating cancer from the face of the earth.
Conclusion:
The current work designs multi epitopes peptide based universal cancer vaccine using MMP9 protein as a target where three Peptides found to be good candidate for interactions with B cells, and ten peptides found as a good target for interactions with each MHC1 and MHC2.
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